Investment Thesis
China Pharma is in severe financial distress with a critical liquidity crisis (current ratio 0.32x), negative gross margins indicating fundamental business problems, and mounting operating losses of $3.2M on only $4.1M revenue. While year-over-year loss improvements and positive free cash flow show marginal operational gains, they are insufficient to overcome the company's inability to generate revenue profitably and dangerously low cash reserves of $345K.
Strengths
- Low debt-to-equity ratio of 0.19x provides some financial flexibility
- Positive free cash flow of $88.9K despite operating losses demonstrates operational discipline
- Net losses improved 32.7% year-over-year showing trend toward breakeven
Risks
- Critical liquidity crisis: current ratio of 0.32x and quick ratio of 0.10x indicate inability to meet short-term obligations
- Negative gross margin of -3.2% reveals fundamental business model problems and unsustainable unit economics
- Declining revenue (-8.5% YoY) combined with $3.2M operating loss creates existential threat to operations
- Minimal cash position of $345K and negative interest coverage ratio of -118.8x threaten near-term solvency
- Zero insider Form 4 filings suggest lack of confidence from management
Key Metrics to Watch
- Current and quick ratios - immediate solvency indicators
- Gross margin trend - must return to positive to demonstrate business viability
- Revenue stabilization and growth - declining sales unsustainable at current burn rate
- Cash position and monthly cash burn rate - critical for survival
Financial Metrics
Revenue
4.1M
Net Income
-3.2M
EPS (Diluted)
$-0.74
Free Cash Flow
88.9K
Total Assets
31.0M
Cash
345.1K
Profitability Ratios
Gross Margin
-3.2%
Operating Margin
-78.2%
Net Margin
-76.9%
ROE
-14.0%
ROA
-10.3%
FCF Margin
2.1%
Balance Sheet & Liquidity
Current Ratio
0.32x
Quick Ratio
0.10x
Debt/Equity
0.19x
Debt/Assets
26.6%
Interest Coverage
-118.77x
Long-term Debt
4.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T09:01:41.591091 |
Data as of: 2025-12-31 |
Powered by Claude AI